MMinoryx Therapeutics
Minoryx Therapeutics is a clinical/registration-stage biotech company based in Mataró (Barcelona) developing novel therapies for orphan central nervous system diseases with high unmet medical need, prioritising paediatric genetic neurometabolic conditions. Its lead asset, leriglitazone (NEZGLYAL, MIN-102), is a brain-penetrant selective PPAR-gamma agonist for X-linked adrenoleukodystrophy that received a positive CHMP opinion in July 2026 for cerebral ALD, with European Commission marketing authorisation expected by end of September 2026; a Phase 2 trial in Rett syndrome (TREE) is due to read out by end of 2026. The company was founded in 2011, spun off its SEE-Tx platform into Gain Therapeutics in 2018, raised a €51M Series C in 2022, and secured a €26.9M IPCEI Med4Cure grant in 2025.
Founders
Global models 5
E
P
N
AIn the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 16
Open as list →
C
Y
C
I
C
E
F
H
C
K
R
S
S
SFunding rounds 5
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2022-05-31 | Series C | €51M |
Columbus Venture Partners, Caixa Capital Risc
+3 more
|
| 2018-09-26 | Series B | €21.3M |
Fund+
+10 more
|
| 2015-10-14 | Series A | €19.4M |
Ysios Capital
+6 more
|
| 2015-01-23 | Seed (estimated) | €2.4M |
Caixa Capital Risc
+4 more
|
| 2013-04-02 | Seed (estimated) | €1.5M | Inveready, Criteria Capital Risc |